Los Angeles Capital Management LLC Sells 1,234 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Los Angeles Capital Management LLC cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 70.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 526 shares of the biopharmaceutical company’s stock after selling 1,234 shares during the period. Los Angeles Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $375,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in REGN. FourThought Financial Partners LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $435,000. Pine Valley Investments Ltd Liability Co raised its stake in Regeneron Pharmaceuticals by 24.7% during the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 6,612 shares of the biopharmaceutical company’s stock valued at $4,710,000 after purchasing an additional 1,309 shares in the last quarter. IFP Advisors Inc lifted its position in Regeneron Pharmaceuticals by 17.2% during the fourth quarter. IFP Advisors Inc now owns 368 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 54 shares during the last quarter. Y Intercept Hong Kong Ltd grew its stake in shares of Regeneron Pharmaceuticals by 22.3% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 11,525 shares of the biopharmaceutical company’s stock worth $8,210,000 after buying an additional 2,100 shares in the last quarter. Finally, Forvis Mazars Wealth Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 3,255 shares of the biopharmaceutical company’s stock worth $2,319,000 after buying an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $684.87 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The business has a 50-day moving average price of $697.91 and a 200 day moving average price of $862.68. The company has a market capitalization of $74.87 billion, a P/E ratio of 17.89, a PEG ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business posted $11.86 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.51%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.